TIFFANY THIBODEAUX: Open Payments
NPI 1265887012 · CARENCRO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,292 in 49 payments from 11 companies in 2025. Trend: 2023 $230 · 2024 $539 · 2025 $1,292
Food & beverage: $1,292
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $459 |
| Otsuka America Pharmaceutical, Inc. | 4 | $176 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $150 |
| E.R. Squibb & Sons, L.L.C. | 3 | $147 |
| ABBVIE INC. | 4 | $141 |
| Supernus Pharmaceuticals, Inc. | 4 | $77 |
| Neurocrine BioSciences, Inc. | 1 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
Products named: ARISTADA, LYBALVI, CAPLYTA, COBENFY, VRAYLAR, ABILIFY MAINTENA, Qelbree, REXULTI.
Industry payments across LA — which companies pay providers there.
